{
  "pmcid": "5584556",
  "sha256": "87469b642c9857ebbd4fcb04a64a193e9d82202e9c358d8b99aa54c5cbfcd847",
  "timestamp_utc": "2025-11-09T16:04:35.597105+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.309712578258395,
    "reading_ease": 31.571364541832708,
    "word_count": 251
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "One hundred forty-eight stage IIâ€“III rectal cancer patients"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 1,
        "evidence": "Our objective was to establish a correlation between specific KRAS mutations and rectal cancer response to CRT"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Tumors with any KRAS mutation were less likely to have a pCR compared to wildtype KRAS (p=0.006)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 4,
    "max_score": 25
  }
}